The rule that changes everything: 21 CFR 812.18(a) and the non US sponsor problem
Under 21 CFR 812.18(a), a company outside the United States cannot itself sponsor an FDA Investigational Device Exemption study. A US person must act as sponsor, and that obligation applies fully to an Early Feasibility Study. This single regulatory fact reshapes nearly every project plan a non US device company builds when it first considers bringing its first in human work to the United States.
EFS in the US versus FIH in Europe: what actually changes for the sponsor
In a European first in human study, the device developer typically acts as sponsor directly under applicable national clinical trial regulations, appoints a principal investigator, and works through a notified body or competent authority process without a mandatory local legal surrogate. In a US Early Feasibility Study, that same company must either establish a qualifying US legal presence or appoint a US Sponsor of Record who accepts full IDE obligations under 21 CFR Part 812, including protocol submission, IRB coordination, adverse event reporting, device accountability, and all correspondence with FDA. The practical burden on the sponsor role is therefore substantially heavier and more formally defined in the US pathway than in most European FIH frameworks.
What the FDA Early Feasibility Study program is designed to do
FDA's Early Feasibility Study program was established to allow sponsors to begin first in human evaluation of a device at an earlier stage of development than traditional IDE pathways typically permitted. According to FDA's guidance document on the EFS program, the agency states: 'An EFS is intended to provide early clinical information to guide device development when definitive information from non-clinical testing is not yet available.'
This framing is important. The EFS pathway is not a shortcut past rigorous safety review; it is a structured mechanism for gathering early human data to inform iterative design. Sponsors using the EFS pathway are still required to submit an IDE application under 21 CFR 812.20, demonstrate a credible benefit-risk rationale, and satisfy all sponsor obligations, including those under 21 CFR 812.18(a). Choosing the US EFS pathway does not remove the 812.18(a) sponsor requirement.
For the full FDA guidance on the EFS program, see the FDA page at FDA Early Feasibility Studies Program.
How widely used is the EFS pathway? What MDIC reports
Adoption of the EFS pathway has grown meaningfully since FDA formalized the program. The Medical Device Innovation Consortium, known as MDIC, has published figures indicating that the EFS program has supported hundreds of studies across cardiovascular, orthopedic, neurological, and other device categories since its launch, with the program demonstrating shorter time to IDE approval compared to traditional IDE submissions for comparable device types. These figures are drawn from MDIC's published program assessments and are attributed here to MDIC; they are not ADB's own data or analysis.
The MDIC data is useful context for founders and regulatory affairs professionals weighing the US EFS pathway against a European FIH study. Time to first patient enrolled, geographic market strategy, investor expectations, and eventual regulatory pathway to clearance or approval all bear on which approach makes more sense for a given program. What the MDIC figures confirm is that the US pathway is active, FDA-engaged, and producing real development-stage clinical data for innovators willing to meet its requirements.
Practical steps sponsors should assess before choosing the US EFS pathway
- Review whether your organization qualifies as a US person under 21 CFR 812.18(a) or whether a US Sponsor of Record arrangement is required.
- Assess the maturity of your preclinical package against FDA's EFS benefit-risk expectations, which accept a higher degree of uncertainty than traditional IDE submissions.
- Prepare your IDE application with an investigational plan, risk analysis, and device description sufficient to satisfy 21 CFR 812.20(b) requirements.
- Review IRB selection, informed consent document structure, and adverse event reporting timelines under 21 CFR 812.150.
- Assess whether a Pre-Submission meeting with FDA would help clarify the agency's expectations before formal IDE submission. ADB's team can support this process at adbccro.com/fda-pre-sub-consulting.
- Use ADB's decision tool to review your sponsor structure options at adbccro.com/us-sponsor-decision-tool.
- Prepare your internal teams using ADB's US Sponsor obligations checklist at adbccro.com/us-sponsor-obligations-checklist.
Nonsignificant risk devices and the EFS pathway
Not every early feasibility evaluation will require a full IDE. If a device qualifies as nonsignificant risk under 21 CFR 812.2(b), an abbreviated requirements pathway may apply. However, the nonsignificant risk determination must be made by an IRB, not unilaterally by the sponsor, and the 21 CFR 812.18(a) sponsor identity requirement applies regardless of risk classification. Sponsors should assess their device's risk classification carefully before assuming an abbreviated pathway is available.
ADB Consulting and the US Sponsor of Record role
ADB Consulting and CRO Inc. serves as US Sponsor of Record for non US device companies conducting FDA-regulated studies, including Early Feasibility Studies under 21 CFR Part 812.
If your organization is planning an EFS or evaluating whether to pursue first in human work in the US rather than Europe, ADB's regulatory team is available to help you assess your options, review your program's readiness, and prepare your submission package. Book a free discovery call with ADB's regulatory team at adbccro.com to discuss your program's specific circumstances and how ADB can support your path forward.
Reviewed November 18, 2026 by ADB's regulatory team.
Frequently asked questions
Can a non US company sponsor an Early Feasibility Study directly with FDA?
No. Under 21 CFR 812.18(a), a company located outside the United States cannot itself act as sponsor for an FDA IDE study, including an Early Feasibility Study. A US person must accept the sponsor role and all obligations that come with it under 21 CFR Part 812. Non US companies typically address this by either establishing a qualifying US legal entity or engaging a US Sponsor of Record such as ADB Consulting and CRO Inc.
How does the US EFS pathway differ from a European first in human study in terms of regulatory burden?
The core difference is formality and federal oversight. In a European FIH study, the sponsor interacts primarily with national competent authorities and ethics committees under frameworks that vary by country. In the US, the sponsor submits an IDE application to FDA under 21 CFR 812.20, is subject to FDA inspection authority, must report adverse events to FDA under defined timelines, and must maintain device accountability records throughout the study. The obligations are codified in federal regulation and FDA has direct enforcement authority over the US sponsor throughout the trial.
Does choosing the EFS pathway mean FDA will approve my device faster?
The EFS pathway is designed to allow earlier stage clinical data collection, not to accelerate ultimate device clearance or approval. It allows sponsors to begin human evaluation with less mature preclinical data than traditional IDE pathways typically require, which can help compress the overall development timeline by generating clinical learning earlier. However, ADB's team can only help you assess your readiness and prepare submissions; we do not and cannot review or prepare materials with any representation about FDA approval outcomes or timelines.
Related reading: a structured Q-Sub meeting preparation process covers this in more depth.
Ready to Navigate the FDA Process with Confidence?
Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.
Book a Free Pathway Call